Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention

Abstract

Gal-3 serum levels measured during hospitalisation could be clinically useful in predicting LVR among patients admitted with anterior STEMI treated by pPCI.

Galectin-3 in acute coronary syndrome

“…Prospective 103 STEMI patients treated by pPCI Elevated Gal-3 levels at baseline are an independent predictor of LVR at 6 month follow-up [49] George et al No association between Gal-3 and heart failure [4] MI, myocardial infarction; STEMI, ST-Segment Elevation Myocardial Infarction; N-STEMI, non-ST segment elevation myocardial infarction; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MACO, major adverse clinical outcome; pPCI, primary percutaneous coronary intervention; LVR, left ventricular remodeling; ACS, acute coronary syndrome; CSA, chronic stable angina; MVA, microvascular angina; HF, heart failure; UA, unstable angina; AF, atrial fibrillation.…”

“…In particular, they assessed LV remodeling with extracellular volume fraction (ECV), determined by cardiovascular magnetic resonance (CMR). In a larger cohort comprising 103 STEMI patients treated by pPCI, Di Tano et al found Gal-3 is an independent predictor of LVR after MI [49]. LVR was defined as a ≥ 15% increase in LV end-systolic volume.…”

Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment

“…Although plasma Gal-3 at Day 7 was related to myocardial extracellular volume fraction at six months in patients after acute myocardial infarction [49], other reports on the association of baseline Gal-3 with LV remodeling brought contradictory results [50,51,52]. As to severe AS, circulating Gal-3 did not correlate with percent collagen area or the number of macrophages in tissue samples collected from the basal interventricular septum at the time of valve surgery for AS [22].…”

Research update for articles published in EJCI in 2016

“…Irrespective of LV ejection fraction and infarct size, galectin-3 measured during hospitalization predicted adverse LV remodelling defined as an increase of at least 15% of LV end-diastolic volume after 6 months in patients with anterior STEMI. 25 Furthermore in a translational porcine model of coronary microembolisminduced postischaemic cardiac remodelling, galectin-3 could be localized in areas of tissue damage and myocardial fibrosis, with proportionate increase in the respective serum galectin-3 expression levels. 26 Another translational murine model could identify galectin-3 as a mediator of postischaemic, macrophage mediated myocardial inflammation and suggested it may represent a potential target for therapeutic inhibition.…”